Salesforce Friends ...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.52 0.04 | 1.01%
06/04/12 - 12:30 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 7.50 | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.99 | 0.58 | 0.98 |
| Price to Sales (TTM) | 2.44 | 4.62 | 1.42 |
| Price to Book (MRQ) | 5.02 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 9.68 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | 8.00 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -5.20 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -48.40 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 56.50 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 21.09 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | n.a. | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.80 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 2.90 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 1.27 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 1.38 | 0.45 | 0.96 |
| Interest Coverage (TTM) | 5.80 | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | 37.60 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -68.22 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 28.80 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -51.60 | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.28 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -46.80 | 5.30 | 7.00 |
| Return on Assets (TTM) | 18.70 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -21.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | 25.60 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -142.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 1,361,260.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | 385,175.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 70.70 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.60 | 0.40 | 0.40 |
Portfolios with EXEL
- Portfolio NameUser Type
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserASCO 2010
- UserBartwaldon Portfolio 1
- UserPART 3 JPMorgan 28th Annual...
Latest EXEL Headlines from TheStreet
- ASCO 2012 Live Blog -- Sunday 06.03.12 | 07:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- Exelixis' Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript) 05.17.12 | 06:05 pm
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Exelixis' Management Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 08:05 pm
- Friday's Top 10 Articles, Videos on TheStreet 05.04.12 | 01:05 pm
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript 05.03.12 | 10:05 pm
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
Press Releases for EXEL
- Cabozantinib Meets Primary Endpoint Of Progression Free Survival In Phase 3 Pivotal Trial In Medullary Thyroid Cancer - Business Wire 06.04.12 | 12:06 pm
- Cabozantinib Demonstrates Evidence Of Anti-Tumor Effects In Heavily Pretreated Patients With Hepatocellular Carcinoma - Business Wire 06.02.12 | 06:06 pm
- Cabozantinib Demonstrates Encouraging Activity In Patients With Heavily Pretreated Metastatic Renal Cell Carcinoma - Business Wire 06.02.12 | 05:06 pm
- Exelixis Announces June 6th Webcast Of Presentation At The Goldman Sachs 33rd Annual Global Healthcare Conference - Business Wire 05.31.12 | 05:05 pm
- Exelixis Initiates COMET-1 Pivotal Trial Focused On Overall Survival In Men With Advanced Prostate Cancer - Business Wire 05.30.12 | 06:05 am
- Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Medullary Thyroid Cancer - Business Wire 05.30.12 | 06:05 am
- Reminder: Exelixis Announces Data Presentations, Webcast Of Investor Briefing In Conjunction With 2012 ASCO Annual Meeting - Business Wire 05.16.12 | 06:05 am
- Exelixis Expands The Cabozantinib Development Program Through NCI-CTEP Collaboration - Business Wire 05.03.12 | 06:05 am
- Exelixis Announces May 8th Webcast Of Presentation At The Deutsche Bank Securities 37th Annual Health Care Conference - Business Wire 05.02.12 | 04:05 pm
- Exelixis Announces May 3rd Webcast Of First Quarter 2012 Financial Results Conference Call - Business Wire 04.19.12 | 04:04 pm
Partner Headlines for EXEL
- Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- UPDATE: Piper Jaffray Downgrades Exelixis to Neutral - Benzinga 11.01.11 | 09:11 am
- Notable Put Options Activity in Exelixis - Benzinga 10.28.11 | 01:10 pm
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- Biotech Gem Exelixis Is Compelling Only for the Long Term - Seeking Alpha 08.19.11 | 05:08 pm
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Exelixis extends timeline for thyroid cancer data - Reuters 07.06.11 | 04:07 pm
